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Abstract
We evaluated the generalizability of a single nucleotide polymorphism (SNP), rs2046210 (A/G
allele), associated with breast cancer risk that was initially identified at 6q25.1 in a genome-wide
association study conducted among Chinese women. In a pooled analysis of over 31,000 women
of East-Asian, European, and African ancestry, we found a positive association for rs2046210 and
breast cancer risk in Chinese women [ORs (95%CI)=1.30(1.22–1.38) and 1.64(1.50–1.80) for the
AG and AA genotypes, respectively, P for trend = 1.54 × 10−30], Japanese women [ORs
(95%CI)=1.31(1.13–1.52) and 1.37(1.06–1.76), P for trend = 2.51 × 10−4], and European-ancestry
American women [ORs (95%CI)=1.07(0.99–1.16) and 1.18(1.04–1.34), P for trend = 0.0069]. No
association with this SNP, however, was observed in African American women [ORs
(95%CI)=0.81(0.63–1.06) and 0.85(0.65–1.11) for the AG and AA genotypes, respectively, P for
trend = 0.4027). In vitro functional genomic studies identified a putative functional variant,
rs6913578. This SNP is 1,440 bp downstream of rs2046210 and is in high LD with rs2046210 in
Chinese (r2=0.91) and European-ancestry (r2=0.83) populations, but not in Africans (r2=0.57).
SNP rs6913578 was found to be associated with breast cancer risk in Chinese and European-
ancestry American women. After adjusting for rs2046210, the association of rs6913578 with
breast cancer risk in African Americans approached borderline significance. Results from this
large consortium study confirmed the association of rs2046210 with breast cancer risk among
women of Chinese, Japanese, and European ancestry. This association may be explained in part by
a putatively functional variant (rs6913578) identified in the region.
Introduction
Breast cancer, one of the most common malignancies among women worldwide, is a
complex polygenic disorder for which genetic factors play a significant role in disease
etiology (1;2). We recently identified a novel genetic susceptibility locus at 6q25.1 for breast
cancer risk in a genome-wide association study (GWAS) conducted among Chinese women
living in Shanghai (3). A nearly 60% elevated risk for breast cancer was found among
women homozygous for the variant A allele in rs2046210, a single nucleotide polymorphism
(SNP) located approximately 29 kb upstream of the ESR1 gene. It has yet to be determined
whether this SNP is associated with breast cancer risk in other populations. Investigation of
the association in other racial and ethnic groups is needed to determine the generalizability
Cai et al. Page 2













of this finding and to identify causal variants for the association. In this paper, we report a
pooled analysis of the association between rs2046210 and breast cancer risk in a consortium
of 14 studies including over 31,000 women of East-Asian, European, and African ancestry.




Fourteen studies contributing a total of 17,188 breast cancer cases and 14,660 controls
participated in this consortium. Detailed descriptions of participating studies are included in
the Supplement. Briefly, the consortium included 18,414 Chinese women from seven studies
conducted in Shanghai [n=10,373; Shanghai Breast Cancer Study (SBCS)-I (3;4), SBCS-II
(3), and Shanghai Breast Cancer Survival Study (SBCSS)/Shanghai Endometrial Cancer
Study (SECS) (3)], Tianjin [n=3,115; Tianjin Study (5)], Nanjing [n=2,084; Nanjing Study
(6;7)], Taiwan [n=2,014; Taiwan Study (8;9)], and Hong Kong [n=828; Hong Kong Study
(10)]; 3,142 Japanese women from three studies conducted in Nagoya [n=1,288; Hospital-
based Epidemiologic Research Program at Aichi Cancer Center (HERPACC-II (11)],
Hawaii [n=1,048; Multiethnic Cohort Study (MEC) (12;13)], and Nagano [n=806, Nagano
Breast Cancer Study (14)]; 8,258 European-ancestry Americans from three studies
conducted in Wisconsin/Massachusetts/New Hampshire [n=3,266; Collaborative Breast
Cancer Study (CBCS) (15;16)], Tennessee [n=3,060; Nashville Breast Health Study
(NBHS) (3)], and New York [n=1,932; Long Island Breast Cancer Study Project (LIBCSP)
(17)]; and 2,034 African Americans from two studies conducted in 12 southern U.S. states
[n=1,568; Southern Community Cohort Study (SCCS) (18)] and Tennessee [n=466; NBHS]
(Table 1).
Genotyping
Genotyping assays were performed at six different centers. The genotyping assay protocol
was developed and validated at the Vanderbilt Molecular Epidemiology Laboratory, and
TaqMan genotyping assay reagents were provided to investigators of the Tianjin study
(Tianjin Cancer Institute and Hospital), Nanjing study (Nanjing Medical University),
LIBCSP (Columbia University), MEC (University of Southern California), and Nagano
Breast Cancer study (Japan National Cancer Center), who conducted the genotyping assays
at their own laboratories. Samples from the other eight studies were genotyped at Vanderbilt
using TaqMan and Affymetrix SNP arrays or at Proactive Genomics using the iPlex™
Sequenom MassArray® platform. The Shanghai study samples were genotyped with
Affymetrix Genome-Wide Human SNP Array 5.0 or 6.0 (Stage 1 of the initial GWAS) and
Sequenom (Stages 2 & 3) as described previously (3). The SCCS samples were genotyped
with Sequenom. All other samples were genotyped with the TaqMan assay.
Genotyping quality controls
Quality control (QC) procedures for samples from the Shanghai studies have been described
previously (3). The consistency rate was 99.7% based on 2,572 comparisons with blinded
QC samples and 99.2% based on 1,751 comparisons with HapMap DNA samples. For the
SCCS samples genotyped with the Sequenom platform, two negative controls, two blinded
duplicates, and two samples from the HapMap project were included in each 96-well plate.
The QC consistency rate was 100% for blinded duplicates and 100% for the HapMap
samples comparing genotyping data obtained from the current study with data obtained from
the HapMap project. For TaqMan genotyping assays conducted at the Vanderbilt Molecular
Epidemiology Laboratory, two negative controls and two blinded duplicates were included
in each 96-well plate, along with 30 unrelated European and 45 Chinese samples from the
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HapMap project for QC purposes. The consistency rate was 98.8% for the blinded duplicates
and 100% for the HapMap samples comparing genotyping data obtained from the current
study with data obtained from the HapMap project. Each of the non-Vanderbilt laboratories
was asked to genotype a trial plate containing DNA from 46 unrelated European-ancestry
and 70 Chinese-ancestry samples before the main study genotyping was conducted. The
consistency rate across all centers for these trial samples was 100% compared with
genotypes previously determined at Vanderbilt. In addition, replicate samples comparing 3–
7% of all study samples were dispersed among the genotyping plates at all centers. The
genotype distribution for rs2046210 was in Hardy-Weinberg equilibrium among controls for
all participating studies with the exception of control samples from the Taiwan study
(P=0.003). The genotype distributions for rs6929137, rs3734804, rs6913578, and rs7763637
were in Hardy-Weinberg equilibrium among controls for all participating studies.
Imputation
In order to evaluate the association of breast cancer risk with SNPs that were not directly
genotyped in the initial GWA scan, we imputed the genotypes of these SNPs using the
program MACH (19). MACH determines the probability distribution of missing genotypes
conditional on a set of known haplotypes, while simultaneously estimating the fine-scale
recombination map. For the Shanghai studies, the imputation was based on 660,118
autosomal SNPs genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 with a
minor allele frequency (MAF) >1% that passed the QC check and using phased HCB/JPT
data from HapMap Phase II (release 22). For the National Cancer Institute Cancer Genetic
Markers of Susceptibility (CGEMS) study (20), genotypes were imputed based on 513,602
autosomal SNPs genotyped using Illumina HumanHap550 BeadChip with a MAF >1% and
phased CEU data from HapMap Phase II (release 22). Logistic regression was used to
estimate the association of imputed SNPs of interest with breast cancer risk taking into
account the degree of uncertainty of genotype imputation.
Plasmid constructs and luciferase assays
DNA fragments carrying the minor alleles of study SNPs were amplified by using PCR and
cloned upstream of a luciferase reporter vector, pGL3 promoter or pGL3 basic (Promega,
WI). The major alleles were generated by using a QuickChange Site-Directed Mutagenesis
Kit (Strategene, La Jolla, CA). Details on PCR primers and site-specific mutagenesis
oligonucleotides are provided in the Supplement. All DNA constructs were verified by
sequencing analysis. Enhancer and promoter activities were determined by transient
transfection followed by an in vitro luciferase assay in HEK293 cells. Transfection was
performed with the use of FuGene 6 Transfection Reagent (Roche Diagnostics, Indianapolis,
IN) in triplicate for each of the constructs. Briefly, 2×105 cells were seeded in 24-well plates
and co-transfeced with pGL4.73, a Renilla expressing vector, which served as a reference
for transfection efficiency. Thirty-six to 48 hours later the cells were lysed with Passive
Lysis Buffer and luminescence (relative light units) was measured using the Dual-Luciferase
Assay System (Promega, WI). Regulatory activity was measured as a ratio of firefly
luciferase activity to Renilla luciferase activity, and the mean from at least three independent
experiments are presented.
Electrophoretic mobility shift assay
Biotin-labeled, double-stranded oligonucleotide probes (details in Supplement) containing
either the major or minor allele sequence were synthesized. The probes were incubated with
nuclear protein extracts from HEK293 and MCF7 cells, in the presence or absence of
competitors, i.e. unlabelled probes. Protein-DNA complexes were resolved by
polyacrylamide gel electrophoresis and detected using a LightShift Chemiluminescent
EMSA kit (Pierce Biotechnology, Rockford, IL).
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Individual data were obtained from each study for a pooled analysis. Case-control
differences in selected demographic characteristics and major risk factors were evaluated
using t-tests (for continuous variables) and Chi-square tests (for categorical variables).
Associations between SNPs and breast cancer risk were determined using odds ratios (ORs)
and 95% confidence intervals (CIs) derived from logistic regression models. ORs were
estimated for heterozygotes and homozygotes for the variant A allele compared with
homozygotes for the common G allele. ORs were also estimated for the variant allele based
on a log-additive model and adjusted for age, study site, and ethnicity, when appropriate.
Adjusting for non-genetic risk factors, including age at first live birth, age at menarche, age
at menopause, body mass index, participation in exercise, family history of breast cancer
history, and history of benign breast diseases, did not alter the observed association, and thus
only age- and study site-adjusted results are presented. Heterogeneity across studies and
between ethnicities was assessed with likelihood ratio tests. Stratified analyses by ethnicity,
menopausal status, and estrogen receptor (ER) status were carried out.
Results
The distributions of age and menopausal status for participating studies are shown in Table
1. Higher risk of breast cancer was consistently observed for all known major breast cancer
risk factors, including a family history of breast cancer, a prior history of benign breast
disease, physical inactivity, early onset of menarche, late onset of menopause, and late age
at first live birth (data not shown). Except for the CBCS and SCCS, data on ER status were
available from all studies.
Generalizability of the association of rs2046210 with breast cancer risk
Table 2 presents associations between rs2046210 genotypes and breast cancer risk by study
site and ethnicity. The variant A allele, which was the minor allele in all groups except
African Americans, was associated with increased breast cancer risk in all Chinese studies.
Pooled analyses of samples from all studies conducted among Chinese women (SBCS-I,
SBCS-II, SBCS/SECS, Tianjin, Nanjing, Taiwan, and Hong Kong) produced ORs of 1.30
(95% CI: 1.22–1.38) and 1.64 (95% CI: 1.50–1.80) for the AG and AA genotypes,
respectively (P for trend = 1.54 × 10−30). After excluding from the analysis the Shanghai
data from which the original association was derived, the association with breast cancer was
stronger; ORs were 1.26 (95% CI: 1.14–1.39) and 1.77 (95% CI: 1.55–2.02), respectively,
for the AG and AA genotypes (P for trend = 2.82 × 10−17). SNP rs2046210 was also
associated with increased breast cancer risk in all three studies conducted among Japanese
women (Nagoya, MEC, and Nagano), with pooled ORs of 1.31 (95% CI: 1.13–1.52) and
1.37 (95% CI: 1.06–1.76) for the AG and AA genotypes, respectively (P for trend = 2.51 ×
10−4). The heterogeneity test for results between the Chinese and Japanese studies was not
statistically significant (p=0.42), therefore, all studies conducted among Chinese and
Japanese women were combined into an “East-Asians” group for subsequent pooled
analyses.
Among women of European ancestry, a positive association between the A allele of the
rs2046210 variant and breast cancer risk was found in all three studies (NBHS, CBCS, and
LIBCSP) with directly genotyped data, although the trend test was statistically significant
only in the NBHS (Table 2). SNP rs2046210 was not directly genotyped in the CGEMS
study. Genotype data for this SNP among 1,145 breast cancer cases and 1,142 controls were
imputed (MACH score = 1.00). An association with breast cancer risk was found with ORs
of 1.10 (95% CI: 0.92–1.31) and 1.26 (95% CI: 0.96–1.66) for the AG and AA genotypes,
respectively, which is consistent with the data from the three studies conducted among
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women of European-ancestry included in the current analysis. In pooled analyses of all
samples (5,518 cases/5,027 controls) from women of European-ancestry (NBHS-White,
CBCS, LIBCSP, and CGEMS), ORs were 1.07 (95% CI: 0.99–1.16) and 1.18 (95% CI:
1.04–1.34) for the AG and AA genotypes, respectively (P for trend = 0.0069) (Table 2).
SNP rs2046210 was not associated with breast cancer risk among African Americans (Table
2). In the SCCS analysis of prevalent breast cancer cases, the case and control distributions
of alleles were nearly identical, while among NBHS African Americans the ORs for the AG
and AA genotypes were below 1.0. In pooled analyses of African American samples (812
cases/1,222 controls) from the two studies (SCCS and NBHS-Black), ORs were 0.81 (95%
CI: 0.63–1.06) and 0.85 (95% CI: 0.65 –1.11) for the AG and AA genotypes, respectively (P
for trend = 0.40). The sample size for African Americans included in this study, however,
was small and the frequency of the A allele in the African American population (62.0%) was
considerably higher than that in the East-Asian (34.8%) and European-ancestry (35.5%)
populations. Fig. 1 presents a forest plot summarizing the results of these studies. We also
performed analyses stratified by menopausal and estrogen receptor status and found that the
association with rs2046210 is more evident for ER(−) breast cancer compared with ER(+)
breast cancer (P=0.0004) in East-Asian women but not in women of European ancestry
(Table 3).
Functional genomic studies of the chr 6q25.1 locus
There are two non-synonymous SNPs (rs6929137 and rs3734804) in the C6orf97 gene,
which is in the 6q25.1 locus. These two SNPs are in strong linkage disequilibrium (LD) with
rs2046210 (r2=0.91 in Chinese, 0.87 in Europeans, and 0.001 in Africans for rs6929137;
r2=0.91 in Chinese, 0.56 in Europeans, and 0.42 in Africans for rs3734804). In an attempt to
identify SNPs that may be more strongly associated with breast cancer risk in women of
European ancestry than the originally-reported SNP (rs2046210), we genotyped these two
SNPs in 1,592 European-ancestry American cases and 1,468 controls from the NBHS
(NBHS-White). The variant alleles of the two SNPs were also associated with breast cancer
risk (per variant allele OR = 1.11 (95% CI: 0.99–1.24) for rs6929137 and 1.12 (95% CI:
1.01 –1.24) for rs3734804). The associations, however, were not stronger than the initially-
reported SNP rs2046210 in the NBHS-White group (OR per variant allele = 1.15, 95% CI:
1.04–1.28). These two SNPs are not included in Affymetrix Genome-Wide Human SNP
Array 6.0 and thus we imputed genotype data for these two SNPs. Again, these SNPs
showed a significant association with breast cancer risk in the Shanghai samples (2,073
cases and 2,084 controls) [ORs per variant allele, 1.26 (95% CI: 1.15–1.39) for rs6929137
and 1.27 (95% CI: 1.16–1.39) for rs3734804]. The associations with these two SNPs were
slightly stronger than with the initially-reported SNP rs2046210 identified in the GWAS
(OR per variant allele = 1.25 (95% CI: 1.14–1.36). However, rs6929137 was not associated
with breast cancer risk in African American (21). Thus, further evaluations of these two
SNPs were not conducted.
To evaluate whether SNP rs2046210 has any regulatory function, we conducted luciferase
reporter assays. The reporter construct containing the major G allele and the construct
containing the minor A allele produced similar levels of luciferase activity. The results of a
search for transcription factor binding sites (the “TFBS Conserved” track of the UCSC
Genome Browser (22)) showed that rs2046210 does not alter putative transcription factor
binding..
To identify potential causal SNPs, we performed a series of heterologous promoter and
enhancer assays, focusing on the 36 kb region between the C6orf97 and ESR1 genes. We
divided the 36 kb region (chromosome 6:151,983,304-152,019,420) into 4 parts and used
long-range PCR to amplify 4 DNA fragments [a, 8.6 kb (harboring rs2046210 polymorphic
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site); b, 9.2 kb; c, 9.3 kb; and d, 8.9 kb], then cloned the 4 fragments into both pGL3 basic
and pGL3 promoter vectors (Fig. 2A). The templates for PCR were DNA carrying the minor
or major alleles of SNP rs2046210. The SNP rs2046210A construct carried the minor alleles
of SNP rs2046210 and other SNPs in close proximity and strong LD with rs2046210, while
the rs2046210G construct carried the major alleles of rs2046210 and other SNPs in close
proximity and strong LD with rs2046210. Luciferase activity derived from the fragment “a”
construct in the pGL3 promoter vector with rs2046210A was significantly different from the
fragment “a” construct with rs2046210G (data not shown). To refine the location of
potential causal SNPs, we subdivided fragment “a” into 3 smaller DNA fragments [e, 2.2 kb;
f, 4.1 kb; and g, 2.3 kb] containing either rs2046210A or rs2046210G into the pGL3
promoter vector and carried out luciferase assays. Luciferase activity derived from fragment
“g” with rs2046210A was significantly different from that of fragment “g” with rs2046210G
(data not shown). Six SNPs, including rs2046210, in fragment “g” were associated with
breast cancer risk in Stage 1 of the initial SBCS GWAS. After excluding SNPs that showed
no evidence of alteration of putative transcription factor binding in the database search, we
found 3 candidate SNPs (rs7740686, rs7763637, and rs6913578) in this region (Fig 2A). We
then generated major allele constructs for each of these 3 SNPs by using site-directed
mutagenesis by using the 2.3 kb fragment “g” with the rs2046210A construct as the
template. Luciferase activity was significantly higher in constructs harboring the major
alleles of rs6913578 (rs6913578-A in Fig. 2B) or rs7763637 (rs7763537-G in Fig. 2B)
compared with the corresponding minor alleles (minor alleles in Fig. 2B).
To investigate whether the DNA sequences containing rs6913578 or rs7763637 interact with
nuclear proteins and, if so, whether these SNP alter protein-DNA interactions, we performed
electrophoretic mobility shift assays. We found that the minor allele (C) of rs6913578
significantly altered DNA-protein complex (II) intensity in both HEK293 and MCF7 cells
(Fig. 2C), whereas there was no detectable interaction of rs7763637 with nuclear proteins
(data not shown).
Evaluation of putative functional variants with breast cancer risk
SNP rs6913578 is located 1,440 bp downstream of rs2046210. SNP rs2046210 is in strong
LD with rs6913578 and rs7763637 in Chinese populations (r2 = 0.91 and 0.901,
respectively) and European-ancestry populations (r2 = 0.83 and 0.87, respectively), but is
not in African populations. Both rs6913578 and rs7763637 are associated with breast cancer
risk in Chinese women and European-ancestry Americans, and the association was stronger
than with rs2046210 (Table 4). The positive associations of these SNPs with breast cancer
risk diminished (Table 4) after adjusting for rs2046210, which is not surprising given the
high LD with rs2046210. These two SNPs, rs6913578 and rs7763637, showed weak
associations with breast cancer risk in African Americans (Table 4). After adjusting for
rs2046210, however, the associations in African Americans approached borderline
significance (P for trend = 0.096 and 0.077, respectively).
Discussion
In this pooled analysis of 17,188 cases and 14,660 controls, we confirmed the association of
rs2046210 at 6q25.1 with breast cancer risk among women with Chinese, Japanese, and
European ancestry. In vitro functional genomic studies identified a putatively functional
variant, rs6913578, a SNP 1,440 bp downstream of rs2046210, which is in high LD with
rs2046210 in Chinese and European-ancestry populations, but is not in Africans. SNP
rs6913578 had a stronger association with breast cancer risk in European-ancestry
Americans than rs2046210, the SNP originally associated with breast cancer risk in a
GWAS conducted in a Chinese population., In African Americans, the association of
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rs6913578 with breast cancer risk approached borderline significance after adjusting for
rs2046210.
Genes that are located in the 1 Mb region centered around rs2046210 include PLEKHG1,
MTHFD1L, AKAP12, ZBTB2, RMND1, C6orf211, C6orf97, ESR1, C6orf98, SYNE1, and
NANOGP11. SNP rs2046210 is located 29 kb upstream of the first untranslated region of the
ESR1 gene, 180 kb upstream of the transcription start site of its first exon (3;23), and 6 kb
downstream of the C6orf97 gene. Because of its relative proximity to the ESR1 gene and the
biological function of ER-α, it is possible that SNP rs2046210, or SNPs in LD with it, may
alter ESR1 gene expression and thereby affect susceptibility to breast cancer. A search of
predicted transcription factor binding sites using the “TFBS Conserved” track of the UCSC
Genome Browser (22) indicated that there is no transcription factor binding site on this SNP.
We further scanned for non-coding RNA (Evofold), as well as miRNA/snoRNA/scaRNA
(sno/miRNA), in this region by using the UCSC Genome Browser and found that this SNP
is not in the coding region for any non-coding RNA or miRNA/snoRNA/scaRNA. Our
functional genomic analyses also provided no support for the potential functionality of
rs2046210.
Our in vitro functional genomic experiments indicated that the location of the potential
functional SNPs may be in a 2.3 kb region. Specifically, SNPs rs6913578, which is 1,440 bp
downstream of rs2046210, and rs7763637, which is 947 bp downstream of rs2046210,
altered luciferase reporter activity. These results suggest that these two common SNPs may
influence DNA binding protein interactions and affect the expression of neighboring genes.
We conducted electrophoretic mobility shift assays to examine this hypothesis and
confirmed that the C allele of rs6913578 significantly altered DNA-nuclear protein
interaction. Thus, it is possible that nuclear protein(s) selectively and differently bind to
specific alleles of the rs6913578 polymorphic site resulting in modification of the
transcription of neighboring genes. However, there has been no confirmation to date that the
putative transcription factors or their associated proteins are involved in the regulation of
ESR1, C6orf97, or nearby genes. Interestingly, both rs6913578 and rs7763637 were
associated with breast cancer risk among Chinese women and European-ancestry Americans
(and the associations were stronger than rs2046210 in European-ancestry Americans), but
not among African American women. However, after adjusting for rs2046210, the
association of rs6913578 and rs7763637 with breast cancer risk in African Americans
approached a borderline significance level. Our data demonstrate and highlight the
importance of conducting inter-racial genetic association studies in populations with
different LD structures to identify potential causal genetic variants for breast cancer and
other complex diseases. Further studies will be required to determine causal SNPs related to
breast cancer risk at the 6q25.1 locus.
In a recent study, Stacey et al. (24) reported an association of rs9397435 at the 6q25.1 locus
with breast cancer risk in European, Chinese, and African populations. This SNP is located
2,854 bp downstream of rs2046210 and 1,414 bp downstream of rs6913578 and is only
weakly correlated with rs2046210 in Europeans (r2 = 0.087) and African (r2 =0.039)
populations. The risk allele frequency of this SNP in Asians is approximately 32%,
comparable to that found for rs2046210, but it is very low, only about 6.3% among the
European and African populations. Very recently, Turnbull et al. (25) evaluated the 6q25.1
locus with breast cancer risk in a GWAS conducted among 3,659 European-ancestry cases
and 4,897 similar controls and identified SNP rs3757318 (MAF = 7%) to have the most
significant association with breast cancer risk. This SNP is located ~200 kb upstream of
ESR1 in an intron of the C6orf97 gene and 34,253 bp upstream of rs2046210. SNP
rs3757318 is only weakly correlated with rs2046210 in Europeans (r2 = 0.088), while the
correlation is stronger in Chinese populations (r2 = 0.48). Similarly, SNP rs3757318 is only
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weakly correlated with rs6913578 in European (r2 = 0.038) and Chinese populations (r2 =
0.181). Using imputed data from our GWAS, we showed that rs3757318 was associated
with breast cancer risk with a per variant allele OR of 1.21 (P for trend = 5.4 × 10−4), an
association that is not as strong as rs2046210. It is unclear, however, whether this SNP is
functional or is related to breast cancer risk in women of African ancestry.
Results reported to date from GWAS have clearly shown that GWAS results cannot be
applied uniformly across all ethnic groups. Several SNPs identified in GWAS conducted
among women of European ancestry could not be replicated in Asian-ancestry women (26–
30). In our study, we have shown that the strength of the association with rs2046210 varies
considerably across ethnic groups. This is not surprising given that most, if not all SNPs
identified in GWAS are tagging SNPs, and there exists considerable differences in genetic
architecture across ethnic groups. Fine-mapping studies are needed to identify additional
genetic risk variants and/or causal variants for breast cancer.
Major strengths of our study are its large sample size and its ability to evaluate the
consistency of the findings across multiple studies conducted in different locations and in
populations with different ethnic ancestry. In addition, we conducted functional genomic
studies of this locus to identify possible functional variants. Ancestry informative markers,
however, were not adjusted for in this study. In addition, our in vitro functional experiments
were conducted only on a 36 Kb region and then were narrowed down to 4 common
polymorphisms in a 2.3 Kb region. It is possible that other functional SNPs, both common
and rare, exist at this locus.
In summary, results from this large consortium study confirmed the association of
rs2046210 with breast cancer risk among Chinese women, Japanese women, and European-
ancestry Americans. SNP rs6913578 may be a functional SNP responsible for the observed
association with breast cancer risk of SNPs at the 6q25.1 locus. Additional fine-scale
mapping studies are needed to identify causal variants at this locus.
Précis
Results from this large consortium study broaden the significance of a chromosomal
marker associated with breast cancer risk in women of diverse ancestry.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ORs (95%) per risk allele for breast cancer by study site and ethnicity. The size of the boxes
is proportional to the sample size of each study. The width of the diamonds represents the
range of confident intervals of combined ORs derived from meta-analyses.
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In vitro functional characterization of SNP rs2046210 and other potential functional SNPs in
6q25.1. A. Diagram of cloning strategy. A 36 kb region (chromosome 6:151,983,304–
152,019,420) between the C6orf97 and ESR1 genes was divided into 4 DNA fragments (a–
d), which were separately cloned into pGL3 basic and pGL3 promoter vectors. The 8.6 kb
“a” fragment was further divided to three DNA fragments (e, f, and g) and subcloned into a
pGL3 promoter vector. The “g” fragment harbored 4 SNPs (rs7740686, rs2046210,
rs7763637, and rs6913578). B. Luciferase reporter activity assays: HEK293 cells were
transiently transfected with pGL3 promoter/luciferase reporter constructs containing the 2.3
Kb “g” fragment. 1. Minor Alleles construct: contained the minor alleles for all four SNPs
(rs7740686-T, rs2046210-A, rs7763637-A, and rs6913578 C); 2. Major Alleles construct:
contained the major alleles for all four SNPs (rs7740686-A, rs2046210-G, rs7763637-G, and
rs6913578-A); 3. rs7740686-A construct: containsed the rs7740686 major allele A and the
minor alleles for the other three SNPs; 4. rs2046210-G construct: contained the rs2046210
major allele G and the minor alleles for the other three SNPs; 5. rs7763637-G construct:
contained rs7763637 major allele G and the minor alleles for the other three SNPs; 6.
rs6913578-A construct: contained rs6913578 major allele A and the minor alleles for the
other three SNPs. Relative luciferase activity is shown as the mean ± SD of three
experiments conducted in triplicate (relative to the Minor Allele construct). Statistical
analysis was conducted by using Student's t test to compare the minor and major alleles
(*P<0.01 when compared with the minor alleles, n=9). Relative luciferase activity is shown
as the mean ± SD of three experiments conducted in triplicate (relative to the Minor Alleles
construct). Statistical analysis was conducted using Student's t test to compare the minor and
major alleles (*P<0.01 when compared with the minor alleles, n=9). C. Electrophoretic
mobility shift assays. Nuclear protein extracts from MCF-7 (top panel) and HEK293
(bottom panel) cells were incubated with biotin-labeled probes corresponding to reference
allele (lanes 1–5) or the risk allele (lanes 6–10) of rs6913578 in the absence or presence of
competitors. Lanes 1 and 6, no nuclear extracts; lanes 2 and 7, unlabeled competitor in 200-
fold molar excess; lanes 3 and 8 (5 mM MgCl2), lanes 4 and 9 (2.5 mM MgCl2), and lanes 5
and 10 (1.25 mM MgCl2), no competitor. I: free biotin-labeled probes. II: specific DNA-
protein complex bands.
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